CJC-1295 (No DAC) + Ipamorelin

Mechanistic basis: CJC-1295 without DAC (Mod GRF 1-29) activates GHRH receptors on anterior pituitary somatotrophs, stimulating GH gene transcription and release. Ipamorelin activates GHS-R1a ghrelin receptors through a separate and complementary pathway. When both pathways are stimulated simultaneously, GH release is synergistically amplified beyond what either compound produces alone.

Why no DAC specifically: Without the DAC albumin-binding modification, CJC-1295 has a half-life of approximately 30 minutes. This short half-life produces a discrete, acute GH pulse that closely mimics the timing and shape of endogenous GHRH-driven GH release. The result is a pulsatile GH release pattern rather than the sustained GH elevation produced by the DAC formulation. This is the defining pharmacokinetic distinction between the two stacks.

Dosing implication: The short half-life of both CJC-1295 no DAC and ipamorelin requires multiple daily injections, typically 2-3 times per day, often timed around natural GH pulse windows (early morning and pre-sleep). This is a meaningful practical distinction from the DAC formulation, which requires only weekly dosing.

Important limitation: No clinical or preclinical studies have evaluated this combination in a controlled setting. The dual-pathway rationale is pharmacologically sound but has not been validated in outcomes trials. GH elevation from this stack (like all GH secretagogue research) remains a biomarker outcome, not a proven clinical outcome.

A modified GRF(1-29) peptide with amino acid substitutions at positions 2, 8, 15, and 27 to resist DPP-IV degradation, but without the DAC maleimide group that enables albumin binding. Half-life approximately 30 minutes. Activates GHRH receptors on pituitary somatotrophs, stimulating a discrete pulsatile GH release. Phase II human data exists for the DAC formulation; the no-DAC version shares the same receptor mechanism but has a more limited human pharmacokinetic dataset.

A pentapeptide ghrelin mimetic that selectively activates GHS-R1a receptors. Distinguished from other GHRPs by its selectivity, it does not elevate cortisol, ACTH, or prolactin at research doses. Half-life approximately 2 hours. Complements CJC-1295 no DAC by amplifying GH pulses through the ghrelin pathway simultaneously with GHRH pathway activation.

This stack uses CJC-1295 without DAC, a pharmacokinetically distinct formulation from CJC-1295 with DAC. These are not interchangeable. The differences are mechanistically meaningful, not merely cosmetic.

Individual Compound Evidence

CJC-1295 with DAC has Phase II human pharmacokinetic data. The no-DAC formulation shares the same receptor mechanism but has a more limited human dataset, most human data references the DAC version. Ipamorelin is rated Animal Studies with limited human pharmacokinetic data and a strong preclinical selectivity profile. Neither compound has published clinical outcomes data for body composition, performance, or anti-aging.

Combination Evidence

No controlled studies have evaluated CJC-1295 no DAC and ipamorelin in combination. The dual-pathway rationale is pharmacologically supported but the combination has not been tested in outcomes trials. GH elevation from this stack is a theoretical extrapolation from the individual compound profiles.

Known Individual Profiles

CJC-1295 DAC Phase II data reported mild injection site reactions and transient flushing. Ipamorelin is distinguished by its selectivity, no cortisol, ACTH, or prolactin elevation at research doses. The no-DAC formulation is assumed to share the safety profile of the DAC version given the identical mechanism, but this has not been independently confirmed.

Combination Safety. Unknown

No safety data exists for the combination. Long-term effects of repeated pulsatile GH elevation, including effects on IGF-1 levels and associated cancer risk considerations, are not characterized for this specific protocol.